Page 1/30 A Prospective Precision Medicine Phase 3 Clinical Trial of Low-dose Ondansetron (a 5-ht3 Antagonist) to Treat Heavy and Very Heavy Drinkers With Alcohol Use Disorder Bankole Johnson (  bjohnson@adialpharma.com ) Adial Pharmaceuticals Inc Hannu Alho University of Helsinki Giovanni Addolorato Catholic University of Rome Otto Lesch Medical University of Vienna Jonathan Chick Castle Craig Hospital Lei Liu Washington University in St. Louis Jack Reich Adial Pharmaceuticals Inc. Vinzant Schuyler Adial Pharmaceuticals Inc. Zachary Rodd Adial Pharmaceuticals Inc Article Keywords: Posted Date: January 30th, 2023 DOI: https://doi.org/10.21203/rs.3.rs-2389870/v1 License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License